This clinical trial is focused on studying the effects of a medication called clebopride on a condition known as Rumination Syndrome. Rumination Syndrome is a digestive disorder where food that has been swallowed comes back up into the mouth from the stomach, often shortly after eating. The study will compare the effects of clebopride, which is taken as a tablet, with a placebo tablet that looks the same but does not contain any active medication.

The purpose of the study is to evaluate how well clebopride works in treating the symptoms of Rumination Syndrome. Participants in the study will take clebopride tablets three times a day for a certain period, and then switch to taking placebo tablets for another period. This is known as a crossover trial, where each participant receives both the medication and the placebo at different times. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is taking clebopride and who is taking the placebo during the study periods.

Throughout the study, participants will be asked to evaluate their symptoms and overall treatment experience using a simple scoring system. This will help researchers understand the effectiveness of clebopride in reducing the symptoms of Rumination Syndrome. The study will also look at other factors, such as the severity of symptoms and quality of life, to provide a comprehensive assessment of the treatment’s impact. The trial is expected to continue until the end of 2025.